Global Nucleic Acid Based Gene Therapy Market Forecast 2026–2035: Long-Term Growth Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
How is the Nucleic Acid Based Gene Therapy Market size predicted to change over the forecast window of 2026–2035?
The nucleic acid based gene therapy market size has demonstrated rapid growth in recent years. It is anticipated to increase from $0.88 billion in 2025 to $0.97 billion in 2026, maintaining a compound annual growth rate (CAGR) of 10.2%. The observed growth during the historical period stems from progress in molecular biology research, a deeper understanding of genetic disease mechanisms, an increase in clinical trials for gene therapies, elevated investment in biotechnology research, and early regulatory approvals for nucleic acid therapies.
The nucleic acid based gene therapy market is anticipated to experience substantial growth in the upcoming years. It is projected to reach $1.44 billion by 2030, displaying a compound annual growth rate (CAGR) of 10.4%. The expansion observed during this forecast period can be linked to factors such as the increasing adoption of crispr-based treatments, a rising demand for rare disease therapies, the expansion of gene therapy manufacturing facilities, a growing emphasis on personalized oncology treatments, and increased public and private funding for genetic medicine. Significant trends expected during this period include a greater adoption of rna-based therapeutics, an increasing use of viral and non-viral gene delivery systems, a heightened focus on targeted gene editing technologies, the proliferation of personalized genetic therapies, and an enhanced emphasis on precision medicine applications.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp
Which Drivers Are Contributing To The Expansion Of The Nucleic Acid Based Gene Therapy Market?
The anticipated expansion of the nucleic acid based gene therapy market is set to be driven by increasing financial backing from both governmental bodies and private enterprises. This financial backing encompasses monetary investments, grants, and subsidies extended by public or private entities to foster the research, development, and subsequent commercialization of these therapies. The surge in financial aid stems from a global heightened emphasis on addressing rare and genetic conditions for which effective treatments are currently lacking. Government funding directed towards nucleic-acid–based gene therapy significantly speeds up advancements by furnishing vital resources for research, clinical trials, and essential infrastructure, thereby directly propelling innovation and the translation into successful treatments. A notable illustration of this occurred in July 2023, when the U.S. National Institutes of Health, a U.S.-based federal health research agency, allocated over $140 million to accelerate genome editing approaches, including CRISPR and other nucleic acid technologies, aimed at rare neurological and blood disorders. This figure represents a considerable increase compared to the $92 million in annual funding provided in 2022. Consequently, the growing financial support from governments and companies is propelling the growth of the nucleic acid based gene therapy market.
What Segment Categories Are Covered In The Nucleic Acid Based Gene Therapy Market?
The nucleic acid based gene therapy market covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
Subsegments:
1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)
2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies
3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)
4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs
5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes
6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers
7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)
Which Market Trends Are Opening Growth Opportunities In The Nucleic Acid Based Gene Therapy Market?
Leading companies operating within the nucleic acid-based gene therapy market are concentrating on personalized, autologous stem-cell therapies, such as genetically modified hematopoietic stem-cell infusions, to address rare inherited diseases. Autologous therapies involve extracting a patient’s own stem cells, genetically correcting them, and re-infusing them to restore missing biochemical functions. For instance, in March 2024, Orchard Therapeutics, a US-based company that offers pharmaceuticals, announced the U.S. Food and Drug Administration’s approval of Lenmeldy (atidarsagene autotemcel) for children with metachromatic leukodystrophy (MLD). Lenmeldy functions by utilizing the patient’s own hematopoietic stem cells, which have been genetically modified to express a functional ARSA gene, thus enabling enzyme restoration in the nervous system. This regulatory accomplishment emphasizes how businesses can commercialize intricate, autologous gene therapies despite facing elevated manufacturing costs.
Which Major Industry Participants Are Leading The Nucleic Acid Based Gene Therapy Market Growth?
Major companies operating in the nucleic acid based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
Access The Complete Report For Deeper Market Insights:
Which Geographic Areas Are Emerging As Strong Markets For The Nucleic Acid Based Gene Therapy Market?
North America was the largest region in the nucleic acid-based gene therapy market in 2025. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Nucleic Acid Based Gene Therapy Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2820&type=smp
Browse Through More Reports Similar to the Global Nucleic Acid Based Gene Therapy Market 2026, By The Business Research Company
Genes Therapy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Cell And Gene Therapy Clinical Trial Services Global Market Report 2026
Cell And Gene Therapy Supply Chain Or Logistics Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
